GLSI Logo

Greenwich LifeSciences, Inc. (GLSI) 

NASDAQ
Market Cap
$160.5M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
89 of 958
Rank in Industry
68 of 549

Largest Insider Buys in Sector

GLSI Stock Price History Chart

GLSI Stock Performance

About Greenwich LifeSciences, Inc.

Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 …

Insider Activity of Greenwich LifeSciences, Inc.

Over the last 12 months, insiders at Greenwich LifeSciences, Inc. have bought $3.53M and sold $0 worth of Greenwich LifeSciences, Inc. stock.

On average, over the past 5 years, insiders at Greenwich LifeSciences, Inc. have bought $1.41M and sold $0 worth of stock each year.

Highest buying activity among insiders over the last 12 months: Patel Snehal (CEO and CFO) — $3.48M. Thompson Jaye (VP Clinical Reg Affairs) — $55,140.

The last purchase of 1,000 shares for transaction amount of $12,910 was made by Thompson Jaye (VP Clinical Reg Affairs) on 2024‑11‑21.

List of Insider Buy and Sell Transactions, Greenwich LifeSciences, Inc.

2024-11-21PurchaseVP Clinical Reg Affairs
1,000
0.0077%
$12.91$12,910+4.16%
2024-09-26PurchaseCEO and CFO
1,500
0.0114%
$14.63$21,9450.00%
2024-08-12PurchaseVP Clinical Reg Affairs
800
0.0065%
$13.85$11,080+3.55%
2024-08-06PurchaseCEO and CFO
2,000
0.0151%
$13.81$27,620-2.43%
2024-08-05PurchaseCEO and CFO
5,500
0.0424%
$13.18$72,490+4.45%
2024-08-02PurchaseVP Clinical Reg Affairs
1,000
0.0082%
$15.15$15,150-3.66%
2024-07-23PurchaseCEO and CFO
1,500
0.0115%
$15.89$23,835-2.14%
2024-07-18PurchaseVP Clinical Reg Affairs
1,000
0.008%
$16.00$16,000-10.24%
2024-06-13PurchaseCEO and CFO
174,825
1.3679%
$14.30$2.5M-5.22%
2024-04-01PurchaseCEO and CFO
3,000
0.0234%
$19.08$57,240-26.47%
2024-03-22PurchaseCEO and CFO
2,500
0.0198%
$19.98$49,950-28.59%
2024-03-20PurchaseCEO and CFO
1,500
0.0112%
$17.68$26,520-23.50%
2024-03-05PurchaseCEO and CFO
30,500
0.2372%
$12.49$380,945+11.81%
2024-03-04PurchaseCEO and CFO
4,100
0.0318%
$13.03$53,423+9.18%
2024-02-16PurchaseCEO and CFO
10,800
0.0835%
$11.16$120,528+24.91%
2024-02-15PurchaseCEO and CFO
12,700
0.1073%
$11.07$140,589+20.95%
2023-11-10PurchaseCEO and CFO
5,000
0.0391%
$10.17$50,838+34.86%
2023-11-03PurchaseCEO and CFO
3,500
0.0274%
$9.11$31,885+49.39%
2023-10-27PurchaseVP Clinical Reg Affairs
500
0.0039%
$8.57$4,285+57.63%
2023-10-26PurchaseCEO and CFO
2,500
0.0188%
$7.97$19,925+62.39%

Insider Historical Profitability

84.25%
Patel SnehalCEO and CFO
5536102
42.1166%
$12.21600+26.3%
Thompson JayeVP Clinical Reg Affairs
264148
2.0095%
$12.21210<0.0001%
McWilliams Daviddirector
620301
4.719%
$12.2130+414.35%
Hallock Kennethdirector
397304
3.0225%
$12.2140+468.96%
Rothe Ericdirector
313226
2.3829%
$12.2110+604.51%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
The Vanguard Group$4.45M1.73223,102+0.64%+$28,314.80<0.0001
Millennium Management LLC$1.27M0.563,811+454.35%+$1.04M<0.01
Geode Capital Management$1.16M0.4558,244+24.41%+$227,928.40<0.0001
BlackRock$1.13M0.4456,459-1.21%-$13,738.67<0.0001
Goldman Sachs$827,610.000.3241,505New+$827,610.00<0.0001
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.